Discovery/R&D

41. The AAV Vector Challenge With Selecta's Dr. Carsten Brunn 1/12/2021

    The Business of Biotech kicks off our Cell & Gene Miniseries with Dr. Carsten Brunn, President & CEO at Selecta Biosciences. Guest host Erin Harris, chief editor at cellandgene.com, joins us for a discussion on Selecta's ImmTOR platform and how the company is addressing the immunogenicity of adeno-associated virus (AAV) vectors challenge faced by gene therapy companies.

42. Gene Tx For Renal Disease With Purespring CEO Richard Francis 5/2/2022

    Purespring Therapeutics launched in 2020 on the back of IP developed by renowned kidney researcher Prof. Moin Saleem, who spent decades working on podocytes when podocytes weren’t cool. Just two years later, the company boasts three gene therapy assets and a platform developed expressly to identify new therapeutic targets to address kidney disease. 

43. Multimodal R&D Management With Incyte's Jim Lee, M.D., Ph.D. 1/18/2024

    Success at multimodal, multi-indication, deep-pipelined Incyte—where commercial operations are as familiar as pre-discovery activity is—begins at the earliest opportunity to achieve research and discovery efficiencies.

44. RNA-Based Therapeutics With Nutcracker Therapeutics' Dr. Geoff Nosrati 11/21/2022

    Nutcracker Therapeutics is a preclinical biopharma company developing multimodal RNA-based therapeutics for HPV-driven tumors, T-cell lymphoma, and Genitourinary tumors. On this episode of the Business of Biotech, Chief Business Officer Geoff Nosrati, Ph.D. offers a comprehensive view of the RNA-based therapeutics landscape and sheds light on what he perceives as an advantageous position at Nutcracker — the capacity to manufacture RNA in-house. If you're curious about the expanding science behind RNA-based therapeutics and their application in biotech, this conversation with a scientist-turned-chief business officer (Nosrati earned his Ph.D. in Biochemistry and Molecular Biology) is a can't-miss episode.

45. BoB@JPM: Self-Replicating RNA With Elixirgen's Akihiro Ko 3/5/2023

    Elixirgen Therapeutics CEO Akihiro Ko joins the Business of Biotech for the final episode in our special series recorded at JPM Week in San Francisco. Life Science Leader Chief Editor Ben Comer joined us for the conversation. We dive deep into Elixirgen's unique, temperature-controlled in-vivo gene expression technology designed to address common cell therapy administration challenges and unwanted, off-target immungenicity effects. Ko also shares progress on the company's ex-vivo candidate EXG-34217, an autologous cell therapy for telomere biology disorders, offers his take on the ever-crowded RNA therapeutics space and how the company is separating itself from the crowd, and much more!

46. Bio & The Business Of Aging with Life Biosciences' Jerry McLaughlin 9/7/2023

    Core to the clinical-stage biopharma Life Biosciences belief set is that "contrary to popular belief, aging is not caused by random wear and tear, but instead is caused by a discrete set of biological mechanisms that can be targeted therapeutically.”

47. Inhalable mAbs & Vaccines With TFF's Glenn Mattes 12/6/2021

    Glenn Mattes' TFF Pharmaceuticals is looking to break the parenteral barrier by manufacturing biologics — mAbs and vaccines, more specifically — that can be inhaled, rather than injected. It's a timely endeavor, and TFF's business model is a collaborative one that seeks to explore dry powder biologic options through partnership, in addition to its own pipeline. On this episode of the Business of Biotech, the veteran biopharma CEO shares the company's vision and the technology that's bringing it into focus.

48. Business of Biotech 2.0 with Ben Comer 3/27/2025

    After nearly five years as host of the Business of Biotech podcast, Matt Pillar is handing the mic over to the voice of the Business of Biotech 2.0, veteran life sciences journalist Ben Comer.

49. Physician + Biotech Builder with Tome Biosciences' Rahul Kakkar, M.D. 4/21/2024

    Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed biotech industry. Dr. Kakkar’s worldview is shaped by his work as a physician—work he continues at Brigham and Women’s Hospital even as he builds Tome Biosciences, where he serves as President & CEO.

50. Functional Ectopic Organs with LyGenesis' Michael Hufford, Ph.D. 4/5/2023

    What sounds like science fiction to some is starting to look like a life changing therapy for millions of liver, kidney, pancreas, and thymus disease sufferers, LyGenesis is developing a pipeline of allogeneic cell therapies using the lymph node as an in vivo bioreactor to grow functioning ectopic organs. The science behind it is being developed not in Boston, not in Philadelphia, nor in San Franciso, but right in the heart of the rust belt in Pittsburgh, PA. This week's episode of the Business of Biotech takes us there for a conversation with LyGenesis CEO Dr. Michael Hufford, Ph.D.